BIOIO
June 24, 2026
Theater 3
Type: Company Presentation
Focus Area:
Metabolic Diseases
BIOIO predicts which drugs will work in humans before clinical trials, and has used this to create a first-in-class diabetes drug.
BIOIO's MOAT (mechanism of action technologies) platform contains two complimentary AI engines: Phasor, a clinical trial success predictor with 93% accuracy -- to our knowledge the highest of any platform -- and Inflector, which has mapped gene-to-drugs and drug-to-genes across 17,710 of the ~20K protein-coding genes (88% accuracy). Together they have produced 11 in vivo or in human validated therapeutic programs spanning metabolic, neurological, oncology, and cardiovascular indications. The lead program, BIOIO-1001, is an insulin sensitizer for Type II Diabetes with a first-in-class mechanism that outperforms established therapies including the GLP-1s in pre-clinical models. Every BIOIO compound begins with in vivo evidence and a predicted composition of matter IP path, reducing the costs and time before committing to expensive experiments.
Company HQ City:
St. Louis
Company HQ State:
MO
Company HQ Country:
United States
Year Founded:
2023
Lead Product in Development:
BIOIO-1001 - first-in-class type II diabetes drug. PPAR-independent insulin Sensitizer, NAD+/proteostasis activator via NMNAT1. Positioned for type II diabetes, and "double diabetes" - combined type I and II diabetes. Stands alone but also synergizes with GLP-1s.
CEO
Tim Peterson-CEO
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
Three. BIOIO-1001, Phasor
When you expect your next catalyst update?
September/October 2026.
What is your next catalyst (value inflection) update?
DC nomination for BIOIO-1001. Expected in late Q3 2026.
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}